🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Felipe Batalini

WinnMed

ORCID: 0000-0003-3354-308X

Also affiliated with Mayo Clinic in Arizona, Mayo Clinic Hospital, Arizona Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1
Top 100%
0DataRank
Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Papers

Driven by 10 papers — median percentile 0. Top paper: “Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer”.

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3045
N/A
1.5DataRank · unranked
64 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

Cell Reports(2022)10.1016/j.celrep.2022.111462
N/A
1.1DataRank · unranked
57 citations

Dan Wang, Olmo Sonzogni, Shizhong Ke, Qi Wang, Abhishek Thavamani +17 more

Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102410
N/A
0.612DataRank · unranked
58 citations

Marisa Cobanaj, Federica Marian, Edward Christopher Dee, Maxwell R. Lloyd, Sara Marcu +6 more

Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)

ESMO Open(2025)10.1016/j.esmoop.2025.105808
N/A
0.292DataRank · unranked
6 citations

Luís Felipe Leite, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Anelise Poluboiarinov Cappellaro, Maria João Gouveia +6 more

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13003
N/A
0.104DataRank · unranked
1 citations

Shizong Ke, Ruolin Liu, Tim Blewett, Justin Rhoades, D. Gulhan +5 more

327 Personalized neoepitope mRNA-based dendritic cell therapies against breast cancer

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0327
N/A
0DataRank · unranked
0 citations

Felipe Batalini, Yining Zhang, Olivier Roy, Akshansh Kaushik, Jin G. Park +4 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1
Top 100%
0DataRank
Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290
Top 100%
0DataRank
Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

(2023)10.1158/1078-0432.c.6532794
N/A
0DataRank · unranked
0 citations

D. Gulhan, Victor Y. Mao, Antuan V. Tran, Madeline Polak, Niya Xiong +14 more

Exposing Vulnerabilities in Clinical LLMs Through Data Poisoning Attacks: Case Study in Breast Cancer

medRxiv(2024)10.1101/2024.03.20.24304627
N/A
0DataRank · unranked
15 citations

Amara Tariq, Felipe Batalini, Boddhisattwa Dhara, Imon Banerjee, Avisha Das